Supplant announces $24m investment

We’re delighted to learn that EBS alumni Dr Tom Simmons and his company Supplant Inc., have just closed a series-A venture capital financing round to commercialise their low-cost sugar replacement made from plant fibre. The company, started in 2017 after 12 months intensive business training from EBS, was originally incorporated as Cambridge Glycoscience Ltd., but re-incorporated in the US as Supplant Inc. after securing a $5M seed round investment via Y-Combinator.

Supplant makes sugars from fibre which can then be used in cookies, cakes and chocolates in the same way cane sugar can, but because the sugars are fibre-derived they behave physiologically in the body like fibre. Supplant’s ingredient is therefore low calorie, has a low impact on blood-sugar levels, and is prebiotic – which actually makes it healthy.

Tom credits investment from Y-Combinator as the turning point for the business. Following the A-round Supplant’s investors now include Manta Ray, Khosla, Felicis, EQT, Coatue and Y-Combinator.

The $24m investment will make a huge difference to Supplant’s ability to transform the food sector. Tom says “the funding will principally be used to go to the market, to scale up the process in the next year or two, and partly to put together a facility in Cambridge on the production side.” The company is now actively recruiting ambitious people to join the company in both commercial and technical roles.

Related posts

Funding for alternative to animal testing

A near-£1 million investment will help University of Dundee spinout company Ten Bio Ltd to commercialise the human skin culture system it developed to provide a viable alternative for many experiments currently performed on animals. EBS provided advice and support […]